Therapeutic Misconception and Scientific Reframing Study (Docket # H-00004365)
Individuals currently suffering from either Major Depression or Breast Cancer are invited to participate in a research study to try to find better ways of explaining clinical research to potential subjects of research, so that they can better understand and make good decisions about whether they want to participate. Participation involves watching a brief PowerPoint presentation on a laptop and completing a brief survey. Participants must be over 18 years of age. Compensation provided. Please call Karen Albert at 508-856-8725 or Debbie Truong at 508-856-5378.
Alcohol Behavioral Couple Therapy for Service Members and Veterans (Docket # H-00003823)
Researchers at UMass Medical School are developing an innovative program for Service Members and Veterans with alcohol-related concerns. The Alcohol Behavioral Couple Therapy Military treatment research program is designed to help service members or veterans and their partners learn skills that will help to reduce drinking and improve relationship functioning. The program will include a thorough assessment, 15 weekly outpatient couple therapy sessions (free of charge), and a follow-up session. Compensation will be provided for the intake and follow-up sessions. For more information, please contact Rachel Rosen at (855) 901-2228 or firstname.lastname@example.org.
Research participation decision-making and research fatigue among youth and parents of youth with chronic health conditions (Docket # H-00007188)
This study seeks youth and young adults (ages 13 through 21) and the parents of youth with HIV, cystic fibrosis and type 1 diabetes who have participated in research studies in the past. We want to learn about people’s experiences and how researchers might better support families who are faced with decisions about whether their child or adolescent will participate in a study for their chronic health condition. This study offers you the opportunity to share your past experiences with participating in clinical research. Compensation is provided. If you might be interested or have questions about this study, please contact Jesica Pagano-Therrien, MSN, RN, CPNP at 774-443-2319 or Jesica.Pagano-Therrien@umassmed.edu for more information.
Schizophrenia and Alcohol Study (Docket # H-00005852)
The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication for those diagnosed with schizophrenia and alcohol use disorder. We seek men and women ages 18 to 65 years. Compensation for your time is available. For more information about the study, please call us at 508-856-MIND (6463) or email MIND@umassmed.edu.
Smoking Study (Docket # H-00007800)
The goal of this study is to determine whether use of a web based decision support system helps patients with schizophrenia stop smoking cigarettes. Compensation will be provided. If you are interested and would like more information, please call 508- 856-MIND (6463) or email MIND@umassmed.edu
Nitroprusside Study (Docket # H-00007610)
The goal of this 6-week research study is to assess the effectiveness of Sodium Nitroprusside, an FDA approved drug for management of hypertension, can improve symptoms of schizophrenia. We seek men and women ages 18-60 with a diagnosis of schizophrenia. Participants will be compensated for their time and travel, and all information will be kept private. For more information about the study, please call 508-856-MIND (6463) or email MIND@umassmed.edu
Exenatide Weekly Injection as an Adjunctive Treatment in Patients with Schizophrenia (Docket # H-00004119)
Have you been diagnosed with Schizophrenia or Schizoaffective disorder? Are you interested in helping us learn if a drug called Exenatide may improve your memory and thinking? If so, you may be eligible to participate in a research study at UMass Medical School. Studies suggest that Exenatide (an FDA-approved drug) can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder. Your participation in the study will last 24 weeks (6 months). You will be compensated (paid) for your time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.
Prelapse Study (Docket # H00007426)
The goal of this study is to compare the standard treatment for psychosis with a treatment version of the medication aripiprazole that is taken only once each month. Study participants at this study location will receive the care your center usually provides. Those who qualify will receive study-related medical exams, and lab tests at no charge. People in this study will be compensated for their time. In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to: male or female aged 18-35 have a clinical diagnosis of psychosis and up to 5 years of antipsychotic medication exposure For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.
Tardive Dyskinesia Study (Docket # H-00006334)
Do involuntary body movements have a hold on you? We invite those who are experiencing involuntary movements in their face or other parts of their body – and suffer from schizophrenia, schizoaffective disorder, bipolar disorder, or mood disorder – to see if they may qualify for the Kinect 3 Study. The purpose of this clinical research study is to evaluate the effectiveness, safety, and tolerability of an investigational oral medication for tardive dyskinesia. Each individual will be evaluated to determine his or her eligibility. Those who qualify will receive study medication, study-related medical exams, and lab tests at no charge. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu. Compensation for time and travel may be available.
Treatment for Marijuana Use and Schizophrenia (Docket # H-00001171)
People who have schizophrenia often abuse marijuana. We are studying whether FDA approved medication Clozapine can reduce marijuana use. The study lasts about 14 weeks and involves weekly meetings with the research staff, answering questions about substance use and current symptoms. Half the people in the study will get a medicine called “clozapine” and the other half will get a medicine called “risperidone”. People in the study will not know which type of pill they are getting. We are looking for people who have been told they have schizophrenia, are willing to take medicine for schizophrenia, use marijuana regularly and are ages 18-55. People in the study will be paid at each meeting for their time. For more information about the study, please call us at 508-856-MIND(6463) or email MIND@umassmed.edu.